Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT2 | P31751 | 2/20 | 0.48 |
| ▸ | AKT1 | P31749 | 1/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.47 |
| ▸ | CFTR | P13569 | 1/20 | 0.47 |
| ▸ | GOPC | Q9HD26 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.38 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.35 |
| ▸ | MYLK4 | Q86YV6 | 3/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7999525 | 0.79 | AKT2 (0.50) | AKT2AKT1ROCK1MYLK4ROCK2 | |
| SCHEMBL17875272 | 0.79 | AKT2 (0.47) | AKT2AKT1ROCK1MYLK4ROCK2 | |
| SCHEMBL6532251 | 0.79 | SMN1; SMN2 (0.50) | AKT2AKT1ROCK1MYLK4ROCK2 | |
| SCHEMBL16156937 | 0.79 | AKT2 (0.45) | AKT2AKT1KMT2AROCK1ROCK2 | |
| SCHEMBL10507198 | 0.78 | IDO1 (0.48) | AKT2AKT1KMT2AMAPK1PAX8 | |
| SCHEMBL28668458 | 0.76 | AKT2 (0.49) | AKT2AKT1MAPK1PAX8ROCK1 | |
| SCHEMBL16046180 | 0.76 | AKT2 (0.71) | AKT2AKT1ROCK1MYLK4 | |
| SCHEMBL155046 | 0.75 | S1PR3 (0.36) | AKT2AKT1KMT2AATMROCK1 | |
| SCHEMBL25129902 | 0.75 | TRPA1 (0.46) | AKT2AKT1ROCK1ROCK2 | |
| SCHEMBL1560439 | 0.75 | AKT2 (0.41) | AKT2AKT1MAPK1ROCK1MYLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3342767-B1 | PYRAZOLYL SUBSTITUTED CARBONIC ACID DERIVATIVES AS MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARM INC (US) | 2021-04-14 | — | — | EP | disclosed |
| US-20200392123-A1 | PYRAZOLYL SUBSTITUTED CARBONIC ACID DERIVATIVES AS MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2020-12-17 | — | — | US | disclosed |
| US-10689372-B2 | Pyrazolyl substituted carbonic acid derivatives as modulators of the prostacyclin (PGI2) receptor useful for the treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2020-06-23 | — | — | US | disclosed |
| US-20190270731-A1 | PYRAZOLYL SUBSTITUTED CARBONIC ACID DERIVATIVES AS MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2019-09-05 | — | — | US | disclosed |
| EP-3342767-A1 | PYRAZOLYL SUBSTITUTED CARBONIC ACID DERIVATIVES AS MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2018-07-04 | — | — | EP | disclosed |
| US-20180030039-A1 | PYRAZOLYL SUBSTITUTED CARBONIC ACID DERIVATIVES AS MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2018-02-01 | — | — | US | disclosed |
| US-9663500-B2 | Pyrazolyl substituted carbonic acid derivatives as modulators of the prostacyclin (PGI2) receptor useful for the treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-20150191455-A1 | PYRAZOLYL SUBSTITUTED CARBONIC ACID DERIVATIVES AS MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2015-07-09 | — | — | US | disclosed |
| US-9012478-B2 | Pyrazolyl substituted carbonic acid derivatives as modulators of the prostacyclin (PGI2) receptor useful for the treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2015-04-21 | — | — | US | disclosed |
| US-20140171469-A1 | PYRAZOLYL SUBSTITUTED CARBONIC ACID DERIVATIVES AS MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2014-06-19 | — | — | US | disclosed |
| US-5849919-A | Fused benzeneoxyacetic acid derivatives which have PGI2 receptor anonist activity | ONO PHARMACEUTICAL CO., LTD. (JP) | 1998-12-15 | — | — | US | disclosed |
| US-5703099-A | TREATMENT OF THROMBOSIS, ARTERIOSCLEROSIS, ISCHEMIC HEART DISEASES, GASTRIC ULCER OR HYPERTENSION | ONO PHARMACEUTICAL CO., LTD. (JP) | 1997-12-30 | — | — | US | disclosed |
| EP-0548949-B1 | Fused benzeneoxyacetic acid derivatives | ONO PHARMACEUTICAL CO (JP) | 1997-09-17 | — | — | EP | disclosed |
| EP-0558062-B1 | Phenoxyacetic acid derivatives and pharmaceutical compositions containing them | ONO PHARMACEUTICAL CO (JP) | 1997-05-07 | — | — | EP | disclosed |
| US-5589496-A | Fused benzeneoxyacetic acid derivatives which have PGI2 receptor agonist activity | ONO PHARMACEUTICAL CO., LTD. (JP) | 1996-12-31 | — | — | US | disclosed |
| US-5536736-A | CARDIOVASCULAR DISORDERS | ONO PHARMACEUTICAL CO., LTD. (JP) | 1996-07-16 | — | — | US | disclosed |
| US-5389666-A | Administering for treatment and prevention of thrombosis, arteriosclerosis, ischemic heart diseases, gastric ulcer or hypertension | ONO PHARMACEUTICAL CO., LTD. (JP) | 1995-02-14 | — | — | US | disclosed |
| US-5378716-A | Prostaglandin agonists | ONO PHARMACEUTICAL CO., LTD. (JP) | 1995-01-03 | — | — | US | disclosed |
| EP-0558062-A2 | Phenoxyacetic acid derivatives and pharmaceutical compositions containing them | ONO PHARMACEUTICAL CO., LTD. (JP) | 1993-09-01 | — | — | EP | disclosed |
| EP-0548949-A2 | Fused benzeneoxyacetic acid derivatives | ONO PHARMACEUTICAL CO., LTD. (JP) | 1993-06-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150191455-A1 | PYRAZOLYL SUBSTITUTED CARBONIC ACID DERIVATIVES AS MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | PTGIR, PTGIS, PTGER1 | AKT2 713/4885AKT1 705/4885SLC6A2 4145/4885 |
| US-20140171469-A1 | PYRAZOLYL SUBSTITUTED CARBONIC ACID DERIVATIVES AS MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | PTGIR, PTGIS, PTGER1 | AKT2 713/4885AKT1 705/4885SLC6A2 4145/4885 |
| US-10689372-B2 | Pyrazolyl substituted carbonic acid derivatives as modulators of the prostacyclin (PGI2) receptor useful for the treatment of disorders related thereto | PTGIR, PTGIS, PTGER1 | AKT2 713/4885AKT1 705/4885SLC6A2 4145/4885 |
| US-20200392123-A1 | PYRAZOLYL SUBSTITUTED CARBONIC ACID DERIVATIVES AS MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | PTGIR, PTGIS, PTGER1 | AKT2 713/4885AKT1 705/4885SLC6A2 4145/4885 |
| US-20180030039-A1 | PYRAZOLYL SUBSTITUTED CARBONIC ACID DERIVATIVES AS MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | PTGIR, PTGIS, PTGER1 | AKT2 713/4885AKT1 705/4885SLC6A2 4145/4885 |
| US-20190270731-A1 | PYRAZOLYL SUBSTITUTED CARBONIC ACID DERIVATIVES AS MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | PTGIR, PTGIS, PTGER1 | AKT2 713/4885AKT1 705/4885SLC6A2 4145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.